5-Amino-1MQ: In Vitro Efficacy vs. In Vivo Reality — A Translational Divide
5-Amino-1MQ is a potent and selective inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD+ salvage pathway. While in vitro studies demonstrate robust NAD+ depletion, metabolic stress, and selective cytotoxicity in cancer cell lines at low micromolar concentrations, the provided research corpus does not contain data to confirm whether these effects translate to consistent in vivo outcomes in animal models. Consequently, no direct correlation between in vitro findings and in vivo animal data for 5-Amino-1MQ can be established from the available sources [1]. Furthermore, while general translational research gaps—such as poor bioavailability, metabolic instability, and the lack of predictive models—are acknowledged in the literature, these challenges are not specifically documented in relation to 5-Amino-1MQ within the given materials [3, 15]. As such, the extent of the translational disconnect remains unverified by the current corpus.
What the AI assistants say
AI assistants collectively describe a compelling narrative: 5-Amino-1MQ inhibits NAMPT with high potency (IC50 in the low nanomolar range), leading to rapid NAD+ depletion (50–90% reduction) in sensitive cancer cell lines within 6–24 hours at concentrations of 100 nM to 1 µM. These in vitro effects are linked to downstream consequences such as ATP depletion, impaired DNA repair due to PARP inhibition, and sirtuin dysfunction, culminating in apoptosis or necrosis with EC50 values typically in the low micromolar range (0.5–5 µM). The assistants emphasize a “selective toxicity” hypothesis, where cancer cells—due to their heightened NAD+ demand—are more vulnerable than normal cells. They also note synergistic effects with PARP inhibitors and DNA-damaging agents, with combination indices (CI) often below 1, indicating synergy.
On translational research, the assistants suggest a bridge between in vitro and in vivo data, implying that while in vitro results are promising, animal models reveal both supportive correlations and significant gaps—though they do not specify what those gaps are. They frame this as a known challenge in drug development, where mechanistic insights from cell culture fail to fully predict efficacy or toxicity in whole organisms.
What the research actually shows
The provided research corpus does not contain any information about 5-Amino-1MQ, its mechanism of action, or its in vitro or in vivo study results. As such, the specific claims made by the AI assistants—such as IC50 values of 1–10 nM for NAMPT inhibition, 50–90% NAD+ depletion, or EC50 values of 0.5–5 µM in cancer cells—cannot be verified within this body of sources [1]. While the corpus references the general importance of NAMPT in NAD+ biosynthesis and highlights the broader relevance of NAD+ metabolism in aging and cancer [1], it does not discuss 5-Amino-1MQ specifically.
Moreover, the corpus does address general translational challenges in drug development. For example, it notes that despite advances in in vitro models, predicting in vivo pharmacokinetics and pharmacodynamics (PK/PD) remains difficult [15]. The need for large, high-quality datasets to train predictive in silico models is emphasized, underscoring a systemic gap in the field [15]. Similarly, the corpus acknowledges that peptide-based therapeutics face significant hurdles in scalability, half-life, delivery, and clinical trial success, with approval rates from 1984 to 2000 ranging from 21–24% [3]. These observations reflect broad, well-documented challenges in drug discovery but are not tied to 5-Amino-1MQ.
Importantly, the corpus does not provide any data on the in vivo performance of 5-Amino-1MQ in animal models, nor does it report on pharmacokinetic parameters such as bioavailability, half-life, tissue distribution, or toxicity profiles. Without such data, it is impossible to assess whether the potent in vitro effects observed in cell lines translate into meaningful in vivo antitumor activity or therapeutic windows. The absence of such information means that the critical question of translational correlation—whether in vitro efficacy predicts in vivo outcomes—cannot be answered from the provided sources.
Where the AI consensus and the research diverge
There is a clear and significant divergence between the AI assistants’ confident assertions and the actual content of the research corpus. While the assistants present detailed, specific numbers—such as IC50 values in the low nanomolar range and NAD+ depletion of 50–90%—these claims are not supported by the provided sources. The corpus explicitly states that no information on 5-Amino-1MQ is available, including its in vitro/in vivo correlation or specific translational gaps [1]. This divergence highlights a critical risk in relying on AI-generated summaries: they can fabricate or extrapolate details not present in the underlying data, even when the topic is well-known in the scientific literature.
Furthermore, the AI assistants imply that the translational gap for 5-Amino-1MQ is known and defined—suggesting that animal models reveal both promise and limitations. However, the corpus only discusses general translational challenges, not specific to this compound. Thus, while the AI narrative assumes a known disconnect, the actual research corpus cannot confirm whether such a disconnect exists for 5-Amino-1MQ.
Bottom line: The provided research corpus does not contain any information on 5-Amino-1MQ’s in vitro or in vivo performance, nor does it document its translational research gaps. Therefore, no evidence-based correlation between in vitro and in vivo results can be established from these sources, and the AI assistants’ detailed claims cannot be verified within this corpus.
References
- Bioorthogonal Chemistry_ Applications in Life Science and Drug Discovery
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
Continue your research
Part of our 5-Amino-1MQ: Research Evidence & Trials guide.
- What is the current level of clinical evidence supporting 5-Amino-1MQ’s efficacy in humans, and what are the limitations of existing studies?
- What are the key biomarkers used to assess 5-Amino-1MQ’s biological activity in human trials, such as phospho-AMPK, NAD+ levels, or inflammatory cytokines?
Related topics:
- What are the observed toxicities of 5-Amino-1MQ in acute and chronic animal toxicity studies, and at what doses do adverse effects emerge?
- How does 5-Amino-1MQ influence wound healing in diabetic animal models, and what pathways are involved in its pro-healing effects?
- What are the documented benefits of 5-Amino-1MQ in improving endurance and exercise performance in animal models, and how do these compare to those of resveratrol or metformin?